Emerging therapeutics for targeting Akt in cancer

Andrew Gdowski, Marlyn Panchoo, Timothy Van Treuren, Alakananda Basu

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt's importance in cell functions such as growth, proliferation and cell survival, many cancer cells rely on this pathway to aid in their survival. This dependence can lead to chemoresistance and selection of more adapted populations of cancer cells. Thus, it is important to understand the functional significance of isoform specificity and its relation to chemoresistance. In this review, we have summarized recent studies on Akt isoform specific regulation as well as each isoform's role in chemoresistance, emphasizing their potential as targets for cancer therapy. We have also condensed ongoing clinical studies involving various types of Akt inhibitors while highlighting the type of study, rationale and co-therapies involved in identifying Akt isoforms as promising therapeutic targets.

Original languageEnglish
Pages (from-to)757-768
Number of pages12
JournalFrontiers in Bioscience - Landmark
Issue number4
StatePublished - 1 Jan 2016


  • Akt Inhibition
  • Akt Isoforms
  • Akt Regulation
  • Akt-mediated Chemoresistance
  • Clinical Trials
  • Review


Dive into the research topics of 'Emerging therapeutics for targeting Akt in cancer'. Together they form a unique fingerprint.

Cite this